Dr Drew Weissman

He holds an MD-PhD and leads a laboratory focused on the study of RNA and innate immune system biology and the application of these findings to vaccine research and gene therapy. Dr Weissman contributed to the development of the modified mRNA technology used in vaccines for preventing COVID-19 infection. He has BA, MA in Biochemistry/Enzymology from Brandeis University in 1981 and MD-PhD in Immunology/Microbiology from Boston University in 1987.